Why AI Will Change Everything, But Not How You Think
One of the upsides of collapsing fertility should be rising incomes for those who choose to work. Fewer workers supporting a fast-rising group of elderly people (and in the UK at least, a fast-rising group of disabled people) should make labor very valuable indeed.
Good news, given how horrible real income growth has been over the last 15 years. If all goes well with this transition to peak humanity, young people might even soon be able to afford to buy houses and have children again.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. CRISPR Therapeutics currently has an average brokerage recommendation (ABR) of 1.88, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 27 brokerage firms. An ABR of 1.88 approximates between Strong Buy and Buy. Of the 27 recommendations that derive the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.6% and 3.7% of all recommendations. Check price target & stock forecast for CRISPR Therapeutics here>>> The ABR suggests buying CRISPR Therapeutics, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Looking at the earnings estimate revisions for CRISPR Therapeutics, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$5.54. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CRISPR Therapeutics. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for CRISPR Therapeutics. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
31 minutes ago
- Yahoo
5 Must-Read Analyst Questions From Manitowoc's Q1 Earnings Call
Manitowoc's first quarter saw a positive market reaction despite revenue and adjusted EPS falling short of Wall Street expectations. Management attributed the quarter's performance to higher orders in the Americas and a sharp uptick in European tower crane demand, with CEO Aaron Ravenscroft highlighting non-new machine sales growth and 'strong customer feedback' at the Bauma trade show. The company also pointed to successful integration of AI into its operational processes, yielding measurable savings, and reported progress in aftermarket initiatives driven by expanded service capabilities. Challenges such as lower overall sales and margin compression were acknowledged, but management focused on the resilience of the aftermarket business and improving order trends. Is now the time to buy MTW? Find out in our full research report (it's free). Revenue: $470.9 million vs analyst estimates of $482 million (4.9% year-on-year decline, 2.3% miss) Adjusted EPS: -$0.16 vs analyst expectations of -$0.09 (71% miss) Adjusted EBITDA: $21.7 million vs analyst estimates of $16.14 million (4.6% margin, 34.4% beat) Operating Margin: 1.3%, down from 3.1% in the same quarter last year Backlog: $793.7 million at quarter end, down 18.3% year on year Market Capitalization: $433.8 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Jerry Revich (Goldman Sachs) asked how tariff mitigation splits between pricing, sourcing, and vendor negotiations. CEO Aaron Ravenscroft explained mitigation involves surcharges, alternative suppliers, and partial cost-sharing with vendors, but emphasized the situation is fluid due to currency and market factors. Revich (Goldman Sachs) inquired about the relative impact of Chinese tariffs and underlying assumptions. Ravenscroft declined to break down the exact China portion, noting tariffs affect both Chinese components and steel/aluminum imports, with mitigation strategies dynamically adjusted as tariffs evolve. Revich (Goldman Sachs) sought detail on the drivers behind accelerating European tower crane orders. Ravenscroft described recovery as broad-based, attributing it to historically low dealer inventories and modest improvements in customer sentiment, but clarified that the market remains far from prior cycle peaks. Steven Fisher (UBS) pressed for clarity on the impact of steel and aluminum tariffs on U.S. production costs. Ravenscroft confirmed these are included in the $45 million estimate for Shady Grove manufacturing, reflecting higher input costs for domestically produced cranes. Fisher (UBS) questioned the ability to reprice backlog orders and sustain non-new machine sales growth. Ravenscroft responded that surcharges are intended to offset tariffs on backlog units, and non-new machine sales growth is 'broad-based' across geographies and product types, supported by ongoing expansion of service technicians and locations. Looking ahead, the StockStory team will be watching (1) the company's ability to sustain aftermarket and non-new machine sales momentum, (2) the effectiveness of tariff mitigation efforts as global trade policy evolves, and (3) continued signs of recovery in European tower crane orders. Execution on service expansion, successful pricing strategies, and progress in key infrastructure projects will also be important markers to track. Manitowoc currently trades at $12.24, up from $8.30 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
The 5 Most Interesting Analyst Questions From Viatris's Q1 Earnings Call
Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, 'We were particularly pleased with our strong execution and growth in Europe and China this quarter,' attributing operational revenue declines mainly to ongoing remediation at the Indore facility and competition in select generic products. Is now the time to buy VTRS? Find out in our full research report (it's free). Revenue: $3.25 billion vs analyst estimates of $3.28 billion (11.2% year-on-year decline, 0.7% miss) Adjusted EPS: $0.50 vs analyst estimates of $0.49 (2.3% beat) Adjusted EBITDA: $923.5 million vs analyst estimates of $903 million (28.4% margin, 2.3% beat) The company reconfirmed its revenue guidance for the full year of $13.75 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $2.23 at the midpoint, a 1.8% increase EBITDA guidance for the full year is $4.04 billion at the midpoint, in line with analyst expectations Operating Margin: -88.6%, down from 5.6% in the same quarter last year Market Capitalization: $10.7 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Chris Schott (JPMorgan) asked about the sales ramp and infrastructure for fast-acting meloxicam and the company's ability to mitigate tariff impacts. CEO Scott Smith detailed ongoing U.S. manufacturing expansion and multiple mitigation strategies, while Chief Commercial Officer Corinne Le Goff emphasized the large addressable market for non-opioid pain treatments. Ashwani Verma (UBS) questioned whether Viatris could increase share repurchases beyond current guidance. CEO Scott Smith indicated the company intends to maintain flexibility, potentially exceeding $650 million in buybacks, depending on macro volatility and tariff developments. David Amsellem (Piper Sandler) probed the timeline for Indore facility remediation and the status of another Indian site. Smith confirmed that re-inspection for Indore is targeted mid-year and that all commitments for the Nashik facility have been met, with ongoing dialogue with the FDA. Bhavin Patel (Bank of America) sought clarity on brand versus generic trends and the sustainability of core business growth. CFO Doretta Mistras pointed to brand strength in China and Europe and indicated that generics outside of Indore are performing in line with expectations. Umer Raffat (Evercore) asked about the safety and use case for fast-acting meloxicam, specifically bleeding risks and hospital versus outpatient use. Chief R&D Officer Philippe Martin reported no increased bleeding risk in studies and highlighted broad potential for both hospital and outpatient use. In the coming quarters, the StockStory team will closely watch (1) regulatory progress and launch timelines for fast-acting meloxicam, XULANE LO, and other key pipeline assets, (2) the resolution of manufacturing challenges at the Indore and Nashik sites, and (3) the company's ability to offset potential tariff headwinds through supply chain adjustments. Execution on new product launches and cost-saving initiatives will be critical markers of operational success. Viatris currently trades at $9.12, up from $8.59 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
